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Percutaneous coronary intervention (PCI) is the main
treatment for the revascularization of coronary arteries in
patients with coronary artery disease. Intracoronary stent
deployment causes arterial wall trauma which elicits a local
inflammatory wound-healing response to mechanical injury
leading to an increase of inflammatory mediators in the
target coronary artery segment [1]. Consequently, an early
systemic inflammatory response is triggered, as observed
by an almost immediate rise (within minutes after PCI) in
systemic inflammatory markers, such as interleukin (IL)-6,
tumor necrosis factor-alpha (TNF-α) and interferon-gamma
(IFN-γ). The production of acute phase reactants in the
liver is stimulated, like C-reactive protein (CRP) and serum
amyloid A protein (SAA), which rapidly increase in the
circulation and which may directly amplify the local
response to the inflammatory stimulus [2, 3]. Furthermore,
coronary stenting in patients with stable angina causes an
elevated systemic inflammatory response compared with
patients treated with angioplasty only [4]. The relationship
of the systemic inflammatory response and restenosis
outcome is still unclear. The majority of the studies show
a correlation between (early) post-PCI systemic inflamma-
tory markers and restenosis outcome [4]. Nonetheless, some
studies report no association [5, 6]. Several factors may
contribute to this discrepancy. First, differences in baseline
demographic, clinical and lesion characteristics may affect
the inflammatory response and, therefore, the clinical
prognosis. More complex lesions and/or lesions presenting
high inflammatory infiltrates may show hypersensitivity to
stent implantation leading to a higher inflammatory
reaction. Second, inflammatory mediators have different
half-lives (e.g., IL-6≈4 h; CRP and SAA≈19 h) and
measurement in a certain time course may not correspond
to their highest peak value and not detect differences in
concentrations between groups. Third, the widespread use
of statins, glycoprotein IIb/IIIa antagonists, and clopidogrel
may attenuate the systemic inflammatory response to PCI
and mask the predictive association between systemic
inflammatory values and clinical outcome. On the whole,
nowadays it is considered that inflammation plays an
important role after PCI with regard to restenosis [7], and
this is strengthened by the fact that polymorphisms in genes
coding for inflammatory proteins, e.g. TNF-α, IL-10,
caspase-1 and colony-stimulating factor 2 (CSF2) have
been shown to be associated and causally involved in
(clinical) restenosis [2, 8–10].
The introduction of drug-eluting stents (DES) in clinical
practice was a milestone in the history of interventional
cardiology. The two initially main worldwide available
DES, i.e. Sirolimus- (SES, Cypher™) and Paclitaxel-
eluting (PES, TAXUS™) stents, reduce restenosis and
target-vessel revascularization rate as compared to bare-
metal stents (BMS) [11–13]. Putative differences in terms
of early systemic inflammatory response among patients
treated with DES versus BMS have been put forward as a
plausible explanation for the DES superiority. Literature
associates DES either with a decrease [14, 15] or no effect
[16, 17] in the early systemic inflammatory response
compared to BMS. The reasons for these unclear results
are unknown, but the same limitations as described above
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for BMS may apply for DES. Head-to-head comparison
between SES and PES continues to absorb the attention of
the interventional cardiology world. There is accumulating
evidence that SES might in some respects be clinically
better than PES [18]. Thus, can differences in terms of early
systemic inflammatory response among patients implanted
with different types of DES relate with the apparent SES
superiority? To answer this question one needs to review
(1) the pivotal phases of restenosis development and (2) the
mechanism(s)-of-action of the pharmacological agent of
each DES. Neointimal hyperplasia is the main cause of in-
stent restenosis and can be defined in three pivotal
characteristic phases: inflammation, granulation and remod-
eling. The major events in the temporal sequence of
restenosis are platelet aggregation, inflammatory cell
infiltration, release of growth factors, medial smooth
muscle cell modulation and proliferation, proteoglycan
deposition and extracellular remodeling. DES pharmaco-
logical active compounds may act on one (or more) of these
key biological processes allowing localized delivery of the
biological active agent directly to the target site of stent
placement. Sirolimus (rapamycin) is an anti-inflammatory,
immunosuppressant, antiproliferative and antimigratory
agent, whereas paclitaxel is primarily a potent antiprolifer-
ative and antimigratory compound [19]. Moreover, one
must keep in mind that first generation DES, like SES
Cypher™ and PES TAXUS™, are three-part component
systems, i.e. drug-polymer coating-stent, and that the drug
may not be the only player when comparing both DES [13].
In the current issue of the Journal, Li et al. [20] assessed
the early systemic inflammatory response after SES and
PES (n=16, respectively) implantation and its relationship
with clinical outcome in patients with single-vessel disease
in a prospective randomized manner. Peripheral blood
samples were taken before PCI, 24 and 72 h after stenting
and plasma concentrations of CRP and IL-6 were deter-
mined. Clinical and angiographic follow-up were per-
formed at 8-months after stenting. The present study
shows that implantation of both types of DES induce an
acute inflammatory response, where SES implantation
results in lower inflammatory responses compared with
PES implantation. This seems to be of clinical relevance
since this difference was associated with the degree of
restenosis at 8-months follow-up. Namely, eight months
clinical outcome data showed a significantly higher in-stent
and in-segment late loss in the PES than in the SES group.
Thus, the present study is particularly interesting because it
is the first to demonstrate that patients undergoing SES
implantation have a lower increase in early systemic
inflammatory markers, as assessed by CRP and IL-6 plasma
concentrations, after PCI as compared to PES. The post-
PCI lower “systemic inflammation” of SES increases the
accumulating body of evidences that SES may be superior
to PES in vascular healing upon PCI insult which may be
associated with better clinical outcomes [18, 21, 22].
The possible association between systemic inflammatory
markers and DES-associated differences has been assessed
earlier. Kim and coworkers [23] performed PCI in patients
(SES, n=29; PES, n=17) who had clinically consistent
stable angina pectoris, single-vessel disease using a single
coronary stent. Peripheral blood samples were obtained
immediately before PCI and at 48 h, 72 h, and 2 weeks
after the procedure. There was no significant difference in
CRP levels between the SES and PES at any time point
studied. Likewise, Gaspardone et al. [24] evaluated patients
with stable coronary artery disease who underwent success-
ful single-vessel/lesion coronary artery stenting. SES were
deployed in 30 patients and PES in 61. Venous blood
samples were obtained at baseline and 24, and 4 h after the
procedure for CRP levels determination. The acute post-
procedural systemic inflammatory response induced by SES
and PES was similar. The incidence of clinical events and
angiographic in-stent restenosis at 12-month follow-up was
comparable in both groups. A recent publication by Kang
and colleagues [25] compared the degree of systemic
inflammation and its relationship to the angiographic out-
comes after SES (n=38) and PES (n=41) implantation in a
prospective, randomized trial. Patients had clinically consis-
tent stable angina pectoris, single de novo target lesions of a
native coronary artery that could be covered by a single
stent. CRP and IL-6 levels were determined before and at 24,
72 h, and 4 weeks after the PCI. There was no significant
difference between the two groups in any of the CRP or IL-6
measurements. At 9-months follow-up, the late lumen loss,
neointimal hyperplasia volume and the percent luminal
reduction were significantly higher in the PES group than
in the SES group. The divergences from the study by Li et
al. [20] and the latter are unknown. Nonetheless, differences
in CRP and IL-6 values at baseline and patient/lesion
characteristics may reflect different inflammatory status in
the different small patient cohorts which may mask modest
increases in these systemic inflammatory markers upon PCI
and could account for the different outcomes. It is
remarkable that although there are currently numerous DES
on the market, with different compounds eluted, there is
surprisingly little data with regard to (vascular) biology
effect, although it is becoming now more and more clear that
not all DES are the same, neither with regard to efficacy nor
with regard to side effects.
In conclusion, the association between DES use and
systemic inflammation is still controversial. Therefore, it is
still early to associate the benefits conferred by SES and a
lower induction of early systemic inflammation factors.
However, the study by Li et al. [20] provides evidences for
further evaluation in larger patient populations with longer-
term follow-up. Further investigations of factors that
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determine the inflammatory response to PCI are needed, for
instance the role of genetic variation of inflammatory
markers with PCI.
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